
BW Offshore: Long-Term Incentive Programme new awards
Long-Term Incentive Programmenewawards
With reference to stock exchange release dated 8 April 2019.
The Board of Directors of BW Offshore Limited ("BWO" or the "Company") has approved the award of share options under the Long-Term Incentive Programme (LTIP) adopted in 2019, to align the interests of the participating employees with those of the Company's shareholders. This is the fifth annual award under the LTIP. The LTIP is discretionary, and participants are invited on an annual basis.
The total number of options awarded under the LTIP for 2023 is 1,849,600 where each option will give the holder the right to acquire one BW Offshore share. A total of 60 BW Offshore employees have been invited to participate in the programme.
The strike price of the options is calculated based on the volume weighted average share price five trading days prior to grant date, plus a premium of 15.76% (corresponding to a 5% increase annually over 3 years). The strike price for the options awarded on 7 March 2023 is NOK 33.04.
The options will have a vesting period of three years, followed by a three-year exercise period. Exercise windows will be set by the Company. The options will expire 6 years after the award date.
The options are non-tradable and conditional upon the option holder being employed by the Company and not having resigned or being terminated for cause prior to the vesting date.
The following primary insiders of the Company have been awarded options under the LTIP for 2023:
1. Chief Executive Officer, Marco Beenen
Options awarded: 293,842
Total number of options: 1,559,372
Shares held: 49,993
2. Chief Financial Officer, Ståle Andreassen
Options awarded: 96,545
Total number of options: 434,355
Shares held: 229,273
3. Chief Commercial Officer, Rune Bjorbekk
Options awarded: 96,545
Total number of options: 512,355
Shares held: 111,424
4. Chief Operating Officer, Kei Ikeda
Options awarded: 96,545
Total number of options: 512,355
Shares held: 24,994
5. General Counsel, Magda K. Vakil
Options awarded: 96,545
Total number of options: 434,355
Shares held: 14,834 (including ownership of close associate)
For further information, please contact:
Ståle Andreassen, CFO, +47 91 71 86 55
Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40
IR@bwoffshore.com or www.bwoffshore.com
About BW Offshore:
BW Offshore engineers innovative floating production solutions. The Company has a fleet of 10 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation21.3.2023 15:48:10 CET | Press release
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1 Sandoz
Articles of Association for RTX A/S21.3.2023 15:28:54 CET | Press release
Nørresundby, Denmark, 21 March 2023 Announcement no. 11/2023 Articles of Association for RTX A/S as adopted at the Annual General Meeting on 26 January 2023 and finally adopted at the extraordinary general meeting on 10 March 2023 (cf. company announcement 10/2023) has been registered and published. The Articles of Association are available at the company’s website www.rtx.dk under: Governance => Articles of Association. Questions and further information: CEO Peter Røpke, tel: +45 96 32 23 00 Attachment RTX A-S - Articles of Association 10 March 2023
Vedtægter for RTX A/S21.3.2023 15:28:54 CET | pressemeddelelse
Nørresundby, den 21. marts 2023 Selskabsmeddelelse nr. 11/2023 Vedtægter for RTX A/S som vedtaget på RTX’s ordinære generalforsamling 26. januar 2023 og endeligt vedtaget på selskabets ekstraordinære generalforsamling 10. marts 2023 (jf. selskabsmeddelelse 10/2023) er blevet registreret og offentliggjort. Vedtægterne er tilgængelige på selskabets hjemmeside www.rtx.dk under: Governance => Vedtægter. Spørgsmål og yderligere oplysninger: CEO Peter Røpke, tlf: +45 96 32 23 00. Vedhæftet fil RTX A-S - vedtægter pr. 10. marts 2023
PARKEN Sport & Entertainment A/S - Bestyrelsesændring21.3.2023 15:24:14 CET | pressemeddelelse
William Kvist genopstiller ikke til bestyrelsen på selskabets ordinære generalforsamling den 21. april 2023. William Kvist har været en del af bestyrelsen siden 2019 og var i en periode også fungerende sportslig leder i F.C. København. Vedhæftet fil 09-2023 Bestyrelsesændring
Forløb af ordinær generalforsamling 2023, 2. meddelelse21.3.2023 15:14:40 CET | pressemeddelelse
Forløb af ordinær generalforsamling 2023, 2. meddelelse Vedhæftet fil Forløb af ordinær generalforsamling 2023, meddelelse 2